Apogee Therapeutics (APGE) Net Cash Flow (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Net Cash Flow data on file, last reported at $320.2 million in Q1 2026.

• Quarterly Net Cash Flow rose 1018.33% year-over-year to $320.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $344.6 million (up 191.03% YoY) and the FY2025 annual result came in at -$10.5 million, down 144.88% from the prior year.
• Net Cash Flow rose to $320.2 million in Q1 2026 per APGE's latest filing, from $23.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $367.1 million in Q1 2024 and bottomed at -$188.5 million in Q3 2024.
• The 5-year median for Net Cash Flow is $4.8 million (2022), against an average of $46.0 million.
• The widest annual swing landed in 2023, when Net Cash Flow jumped 6036.13%; it then tumbled 1122.77% in 2024.
• Tracing APGE's Net Cash Flow over 5 years: stood at $149.3 million in 2022, then sank by 146.65% to -$69.7 million in 2023, then surged by 133.03% to $23.0 million in 2024, then grew by 2.89% to $23.7 million in 2025, then surged by 1252.74% to $320.2 million in 2026.
• Per Business Quant, the three latest APGE Net Cash Flow figures stand at $320.2 million (Q1 2026), $23.7 million (Q4 2025), and -$16.6 million (Q3 2025).

Peer Comparison